(HealthDay)—The 70-gene signature (GS) assay impacts treatment decisions amongst physicians treating sufferers recognized as being at intermediate danger with the 21-gene assay (21-GA), in accordance with a research revealed on-line Oct. 26 in JAMA Oncology.
Michaela Tsai, M.D., from the Virginia Piper Cancer Center in Minneapolis, and colleagues carried out a research involving 840 sufferers with early-stage breast cancer and a 21-gene assay recurrence rating of 18 to 30. Physicians got the 70-GS end result earlier than adjuvant treatment, and the change in doctor treatment decision was assessed earlier than versus after receiving the outcome.
The researchers discovered that receiving the 70-GS classifications was correlated with a big change in adjuvant treatment choice, with an odds ratio of zero.64 for all sufferers. Overall, 28.9 % of low-risk sufferers had chemotherapy faraway from the treatment suggestion, whereas 36.7 % of high-risk sufferers had chemotherapy added. Results of the 70-GS have been related to the doctor’s adjuvant treatment suggestion; 87.eight % of high-risk and 90.6 % of low-risk sufferers have been really helpful to obtain adjuvant chemotherapy or no chemotherapy, respectively. In 78.6 % of instances, physicians reported having extra confidence in their treatment suggestions based mostly on 70-GS outcomes.
“The 70-GS provides clinically actionable information regarding patients classified as intermediate risk by the 21-GA and was associated with a change in treatment decision in 282 of these patients (33.6 percent),” the authors write.
Several authors disclosed ties to biopharmaceutical corporations, together with Agendia Inc., which funded the research.
70-gene signature not cost-effective in breast cancer